Pädiatrie up2date, Table of Contents Pädiatrie up2date 2016; 11(04): 339-361DOI: 10.1055/s-0042-112176 Rheumatologie © Georg Thieme Verlag KG Stuttgart · New YorkSystemische Autoimmunerkrankungen Authors Kirsten Mönkemöller Michael Weiß Recommend Article Abstract All articles of this category(opens in new window) Full Text References Literatur 1 Hospach A. Purpura Schönlein-Henoch. In: Wagner N, Dannecker G, (Hrsg). Pädiatrische Rheumatologie. 2. Aufl. Heidelberg: Springer; 2014: 397-400 2 Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11 3 Ozen S, Pistorio A, Iusan SM et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteriitis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteriitis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69: 798-806 4 Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 2002; 94: 132-137 5 Eleftheriou D, Brogan PA. Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol 2016; 14: 26 6 Chartapisak W, Opastirakul S, Hodson EM et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Database Syst Rev 2009; 8: CD005128 7 Jakob A. Kawasaki-Syndrom. Monatsschr Kinderheilkd 2016; 164: 241-253 8 Duppenthaler A, Borte M, Jakob A, Kallinich T. Kawasaki-Syndrom. In: DGPI e.V, (Hrsg). DGPI Handbuch, Infektionen bei Kindern und Jugendlichen. 6. Aufl. Stuttgart: Thieme; 2013: 755-757 9 Cremer HL. Akutes febriles mukokutanes Lymphadenopathie-Syndrom auch in Deutschland?. Pädiatr Prax 1979; 21: 75-82 10 Neudorf U, Lilienthal E. AWMF-Leitlinie 027/063: Kawasaki-Syndrom/Vaskulitiden. AWMF online. aktueller Stand 01/2013 11 Dannecker G. Kawasaki-Erkrankung. In: Wagner N, Dannecker G, (Hrsg). Pädiatrische Rheumatologie. 2. Aufl. Heidelberg: Springer; 2014: 386-397 12 Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708-1733 13 Kobayashi T, Saji T, Otani T et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-1620 14 Hospach A, Neudorf U, Kallinich T et al. Initiale Glukokortikoidtherapie beim Kawasaki-Syndrom. Empfehlung der Gesellschaft für Kinder- und Jugendrheumatologie im Rahmen der Wörlitzer Konsensusgespräche. Monatsschr Kinderheilkd 2013; 161: 1037-1041 15 Eleftheriou D, Levin M, Shingadia D et al. Management of Kawasaki disease. Arch Dis Child 2014; 99: 74-83 16 Uehara R, Yashiro M, Nakamura Y et al. Kawasaki disease in parents and children. Acta Paediatr 2003; 92: 694 17 Zink A, Minden K, List SM. Entzündlich-rheumatische Erkrankungen. Robert Koch Institut. Berlin : Gesundheitsberichtersatattung des Bundes; 2010: 49 18 Sag E, Tartaglione A, Batu ED et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol 2014; 32: 440-444 19 Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782 20 Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16: 564-571 21 Arıcı ZS, Batu ED, Ozen S. Reviewing the recommendations for lupus in children. Curr Rheumatol Rep 2015; 17: 17 22 Peene I, Meheus L, Veys EM et al. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 2001; 60: 1131-1136 23 Almeida González D, Roces Varela A, Marcelino Rodríguez I et al. Anti-dsDNA antibodies in systemic lupus erythematosus: A combination of two quantitative methods and the ANA pattern is the most efficient strategy of detection. J Immunol Methods 2015; 427: 30-35 24 Brunner HI, Higgins GC, Wiers K et al. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemiclupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 335-344 25 Lattanzi B, Consolaro A, Solari N et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI;. SDI). Arthritis Care Res 2011; 63 (Suppl. 11) 112-117 26 Klein-Gitelman M, Lane JC. Systemic Lupus Erythematodes. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, (eds). Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Elsevier; 2016: 285-317 27 Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 2009; 5: 391-403 28 Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am 2005; 52: 443-467 29 Kuhn A, Bonsmann G, Anders HJ et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 2015; 112: 423-432
